Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Celldex Therapeutics, Inc. (CLDX)

Celldex Q3 net loss widens to $75.6 million; cash falls to $650.3 million

Negative Impact 3 of 5 earnings Written later

Celldex reported third-quarter 2026 results with a net loss of $75.6 million, or $0.96 per share, up from $67.0 million, or $1.01 per share, a year earlier. The company recognized no material revenue, while research and development expenses rose to $67.4 million, and cash, cash equivalents and marketable securities declined to $650.3 million; the company says this funds planned operations through 2028.

Key points

  • Q3 2026 net loss was $75.6 million ($0.96 per share), compared with $67.0 million ($1.01 per share) in Q3 2025.
  • Q3 2026 R&D expenses were $67.4 million, up from $62.9 million, driven mainly by barzolvolimab clinical trial and contract manufacturing costs.
  • Cash and marketable securities were $650.3 million at September 30, 2026, down from $717.6 million at June 30, 2026.
  • The company expects to submit a BLA for barzolvolimab in chronic spontaneous urticaria (CSU) in 2027.

The filing

CompanyCelldex Therapeutics, Inc. (CLDX)
Form8-K, current report
Filed with the SECNov 5, 2026, 4:01 PM ET
Accession number0001171843-26-007174

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:51 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.